Phase I/II clinical trial of WT1 peptide vaccine therapy for lung, breast, pancreas, stomach, and colorectal cancer
收藏NIAID Data Ecosystem2026-03-07 收录
下载链接：
https://www.omicsdi.org/dataset/ecrin-mdr-crc/2626405
下载链接
链接失效反馈官方服务：
资源简介：
Interventions: Seven doses of HLA-A*24-restricted WT1 peptide (3 mg) emulsified with 1-2KE of OK-432 adjuvant will be intradermally injected on bilateral axillary and inguinal areas every 2 weeks. Injection schedule can be changed within 3 days.
Primary outcome(s): Ratios of adverse events PFS: Progression free survival, Overall survival
Study Design: Single arm Non-randomized
创建时间：
2013-07-15
